Biologic therapy in the management of asthma

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Purpose of review Current asthma management relies on inhaled corticosteroids, but some asthma is not well controlled with inhaled steroids alone or in combination with long-acting bronchodilators or leukotriene pathway inhibitors. The field of biologic therapy has grown dramatically in the past two decades, with current availability of three molecules, with two distinct and highly selective approaches to interfering with the allergic and eosinophilic airway inflammation common to most asthma. This review summarizes current and future options for incorporating biologic therapy into the overall management of asthma. Recent findings Two new biologic agents have been recently introduced in the United States market, supported by well controlled, randomized clinical trials. These trials have provided insight into the types of patients who are most likely to benefit from these novel agents. Summary In asthma patients with frequent exacerbations, the addition of a biologic agent targeting the interleukin-5 pathway, or immunoglobulin E, can significantly reduce exacerbations and improve asthma control. The clinical predictors of utility of specific agents overlap with one another, highlighting the importance of clinical judgment in the overall management of this complex disorder.

Original languageEnglish (US)
Pages (from-to)375-382
Number of pages8
JournalCurrent Opinion in Allergy and Clinical Immunology
Volume16
Issue number4
DOIs
StatePublished - Aug 1 2016

Fingerprint

Biological Therapy
Asthma
Biological Factors
Leukotrienes
Bronchodilator Agents
Interleukin-5
Immunoglobulin E
Adrenal Cortex Hormones
Randomized Controlled Trials
Steroids
Inflammation

Keywords

  • benralizumab
  • biologic therapy
  • IL-13
  • IL-17
  • IL-4
  • mepolizumab
  • omalizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Biologic therapy in the management of asthma. / McCracken, Jennifer; Tripple, Julia; Calhoun, William.

In: Current Opinion in Allergy and Clinical Immunology, Vol. 16, No. 4, 01.08.2016, p. 375-382.

Research output: Contribution to journalReview article

@article{23d5a512c91046a387d2962b12e0a0e9,
title = "Biologic therapy in the management of asthma",
abstract = "Purpose of review Current asthma management relies on inhaled corticosteroids, but some asthma is not well controlled with inhaled steroids alone or in combination with long-acting bronchodilators or leukotriene pathway inhibitors. The field of biologic therapy has grown dramatically in the past two decades, with current availability of three molecules, with two distinct and highly selective approaches to interfering with the allergic and eosinophilic airway inflammation common to most asthma. This review summarizes current and future options for incorporating biologic therapy into the overall management of asthma. Recent findings Two new biologic agents have been recently introduced in the United States market, supported by well controlled, randomized clinical trials. These trials have provided insight into the types of patients who are most likely to benefit from these novel agents. Summary In asthma patients with frequent exacerbations, the addition of a biologic agent targeting the interleukin-5 pathway, or immunoglobulin E, can significantly reduce exacerbations and improve asthma control. The clinical predictors of utility of specific agents overlap with one another, highlighting the importance of clinical judgment in the overall management of this complex disorder.",
keywords = "benralizumab, biologic therapy, IL-13, IL-17, IL-4, mepolizumab, omalizumab",
author = "Jennifer McCracken and Julia Tripple and William Calhoun",
year = "2016",
month = "8",
day = "1",
doi = "10.1097/ACI.0000000000000284",
language = "English (US)",
volume = "16",
pages = "375--382",
journal = "Current Opinion in Allergy and Clinical Immunology",
issn = "1528-4050",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Biologic therapy in the management of asthma

AU - McCracken, Jennifer

AU - Tripple, Julia

AU - Calhoun, William

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Purpose of review Current asthma management relies on inhaled corticosteroids, but some asthma is not well controlled with inhaled steroids alone or in combination with long-acting bronchodilators or leukotriene pathway inhibitors. The field of biologic therapy has grown dramatically in the past two decades, with current availability of three molecules, with two distinct and highly selective approaches to interfering with the allergic and eosinophilic airway inflammation common to most asthma. This review summarizes current and future options for incorporating biologic therapy into the overall management of asthma. Recent findings Two new biologic agents have been recently introduced in the United States market, supported by well controlled, randomized clinical trials. These trials have provided insight into the types of patients who are most likely to benefit from these novel agents. Summary In asthma patients with frequent exacerbations, the addition of a biologic agent targeting the interleukin-5 pathway, or immunoglobulin E, can significantly reduce exacerbations and improve asthma control. The clinical predictors of utility of specific agents overlap with one another, highlighting the importance of clinical judgment in the overall management of this complex disorder.

AB - Purpose of review Current asthma management relies on inhaled corticosteroids, but some asthma is not well controlled with inhaled steroids alone or in combination with long-acting bronchodilators or leukotriene pathway inhibitors. The field of biologic therapy has grown dramatically in the past two decades, with current availability of three molecules, with two distinct and highly selective approaches to interfering with the allergic and eosinophilic airway inflammation common to most asthma. This review summarizes current and future options for incorporating biologic therapy into the overall management of asthma. Recent findings Two new biologic agents have been recently introduced in the United States market, supported by well controlled, randomized clinical trials. These trials have provided insight into the types of patients who are most likely to benefit from these novel agents. Summary In asthma patients with frequent exacerbations, the addition of a biologic agent targeting the interleukin-5 pathway, or immunoglobulin E, can significantly reduce exacerbations and improve asthma control. The clinical predictors of utility of specific agents overlap with one another, highlighting the importance of clinical judgment in the overall management of this complex disorder.

KW - benralizumab

KW - biologic therapy

KW - IL-13

KW - IL-17

KW - IL-4

KW - mepolizumab

KW - omalizumab

UR - http://www.scopus.com/inward/record.url?scp=84976869407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976869407&partnerID=8YFLogxK

U2 - 10.1097/ACI.0000000000000284

DO - 10.1097/ACI.0000000000000284

M3 - Review article

C2 - 27362324

AN - SCOPUS:84976869407

VL - 16

SP - 375

EP - 382

JO - Current Opinion in Allergy and Clinical Immunology

JF - Current Opinion in Allergy and Clinical Immunology

SN - 1528-4050

IS - 4

ER -